Analyst Thomas Shrader from BTIG maintained a Buy rating on Bright Minds Biosciences and keeping the price target at $147.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Thomas Shrader has given his Buy rating due to a combination of factors including the strong clinical profile of BMB-101 in difficult-to-treat epilepsies. He highlights that adult absence seizure patients are highly refractory, current therapies are limited, and even partial seizure reductions can materially improve quality of life in a setting where true seizure freedom is rare but increasingly valued.
He also points to BMB-101’s recent Phase 2 data showing substantial seizure reductions in both absence and DEE cohorts, alongside a favorable safety profile and lack of troubling somnolence effects, which differentiates it from existing options. In addition, he views the planned Prader-Willi syndrome trial as a meaningful upside opportunity supported by a mechanism aligned with physician needs, and notes that the company’s rapid clinical progress supports a favorable DCF-based valuation for the stock.